
LB Pharmaceuticals Inc: shareholders and insiders
Price
$39.85
November 19, 2026Market cap $1.3B
What Ploutos Investor adds for LB Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 2 fiscal years, from 2024
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Sorry, we do not have enough data
for purchases and sales by LB Pharmaceuticals's insiders
Why?
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Deep Track Biotechnology Master Fund, Ltd.with 3 more personsShare of class11.7%
- RA Capital Management, L.P.with 3 more personsShare of class8.70%
- Commodore Capital LPwith 3 more personsShare of class6.80%
- BlackRock, Inc.Share of class6.30%
- Pontifax Management 4 G.P. (2015) Ltd.with 3 more personsShare of class6.30%
- Caligan Partners LPwith 1 more personShare of class5.00%
- TCG Crossover GP II, LLCwith 2 more personsShare of class5.00%
- Trails Edge Capital Partners, LPwith 2 more personsShare of class5.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Deep Track Biotechnology Master Fund, Ltd.with 3 more persons | 11.7% | 3.35M | Feb 10, 20262 filings since Sep 19, 2025 | 13D/A | |
| RA Capital Management, L.P.with 3 more persons | 8.70% | 2.21M | Feb 17, 20262 filings since Sep 19, 2025 | 13G/A | |
| Commodore Capital LPwith 3 more persons | 6.80% | 1.97M | May 15, 20262 filings since Sep 18, 2025 | 13G/A | |
| BlackRock, Inc. | 6.30% | 1.80M | Jul 29, 20262 filings since Jan 21, 2026 | 13G/A | |
| Pontifax Management 4 G.P. (2015) Ltd.with 3 more persons | 6.30% | 1.41M | Sep 25, 2025 | 13D | |
| Caligan Partners LPwith 1 more person | 5.00% | 1.44M | May 15, 2026 | 13G | |
| TCG Crossover GP II, LLCwith 2 more persons | 5.00% | 1.45M | Aug 14, 20263 filings since Sep 18, 2025 | 13G/A | |
| Trails Edge Capital Partners, LPwith 2 more persons | 5.00% | 1.27M | Dec 31, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Deep Track Biotechnology Master Fund, Ltd.11.7%From the filing of Feb 10, 2026
Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On February 4, 2026, the Issuer entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors") pursuant to which the Issuer, in a private placement (the "Private Placement"), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the "Shares") of the Issuer's Common Stock and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,417,107 shares of Common Stock (such shares issuable upon exercise of the Pre-Funded Warrants, the "Warrant Shares", and together with the Shares and the Pre-Funded Warrants, the "Securities"). Each…
From the filing of Feb 10, 2026Pontifax Management 4 G.P. (2015) Ltd.6.3%From the filing of Sep 25, 2025
The Reporting Persons acquired the securities reported herein for investment purposes, subject to the following: The Reporting Persons intend to review on a continuing basis the investments in the Issuer by the Reporting Persons. The Reporting Persons may engage in discussions with management, the board of directors of the Issuer (the "Board"), other shareholders of the Issuer and other relevant parties concerning the Reporting Persons' investment in the Issuer's securities. Depending on various factors, including, without limitation, the price and availability of the Issuer's securities, subsequent developments affecting the Issuer, the Issuer's business and the Issuer's prospects, other…
From the filing of Sep 25, 2025
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+4.3%
- Millennium Mgmt (Englander)In the quarter-33%
- D.E. ShawIn the quarter+401%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 91.3K | $3.5M | 0.01% | |
| Citadel Advisors (Griffin) | 225.2K | +4.3% | $8.6M | 0.00% |
| Millennium Mgmt (Englander) | 172.8K | -33% | $6.6M | 0.00% |
| D.E. Shaw | 67.8K | +401% | $2.6M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 17.2% of its shares outstanding were held short, -7.4% since the report before.
- Shares held short
- 5.56M
- 17.2%
- Since the report before6.01M on Sep 30, 2026
- -7.4%
- 12.1
- 458.5K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 95%
- Report date
- Oct 15, 2026
- Shares held short
- Sep 15, 2025: Shares held short 126.6K
- Sep 30, 2025: Shares held short 198.5K
- Oct 15, 2025: Shares held short 276.2K
- Oct 31, 2025: Shares held short 223.0K
- Nov 14, 2025: Shares held short 249.8K
- Nov 28, 2025: Shares held short 242.5K
- Dec 15, 2025: Shares held short 464.6K
- Dec 31, 2025: Shares held short 1.83M
- Jan 15, 2026: Shares held short 1.79M
- Jan 30, 2026: Shares held short 1.80M
- Feb 13, 2026: Shares held short 2.20M
- Feb 27, 2026: Shares held short 2.62M
- Mar 13, 2026: Shares held short 2.71M
- Mar 31, 2026: Shares held short 2.62M
- Apr 15, 2026: Shares held short 3.11M
- Apr 30, 2026: Shares held short 3.80M
- May 15, 2026: Shares held short 4.02M
- May 29, 2026: Shares held short 4.02M
- Jun 15, 2026: Shares held short 4.30M
- Jun 30, 2026: Shares held short 4.55M
- Jul 15, 2026: Shares held short 4.26M
- Jul 31, 2026: Shares held short 4.75M
- Aug 14, 2026: Shares held short 5.16M
- Aug 31, 2026: Shares held short 5.28M
- Sep 15, 2026: Shares held short 5.62M
- Sep 30, 2026: Shares held short 6.01M
- Oct 15, 2026: Shares held short 5.56M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading54.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 54.2% of the shares in the reported trades were short sales, against 75.3% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 54.2%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 75.3%
- Change
- -21.1 pts
- Short sales a dayon average, of 179.8K shares
- 97.4K
- More than atof 3,656 US-listed companies, same days
- 64%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 69%
- Oct 13, 2026: Short sales 72.2%
- Oct 14, 2026: Short sales 59.6%
- Oct 15, 2026: Short sales 77.9%
- Oct 16, 2026: Short sales 87.3%
- Oct 19, 2026: Short sales 74.2%
- Oct 20, 2026: Short sales 68.6%
- Oct 21, 2026: Short sales 82.2%
- Oct 22, 2026: Short sales 67.6%
- Oct 23, 2026: Short sales 69.9%
- Oct 26, 2026: Short sales 73.2%
- Oct 27, 2026: Short sales 65%
- Oct 28, 2026: Short sales 80%
- Oct 29, 2026: Short sales 83.6%
- Oct 30, 2026: Short sales 55.4%
- Nov 2, 2026: Short sales 60.6%
- Nov 3, 2026: Short sales 62.7%
- Nov 4, 2026: Short sales 50.7%
- Nov 5, 2026: Short sales 58.6%
- Nov 6, 2026: Short sales 49.7%
- Nov 9, 2026: Short sales 49.9%
- Nov 10, 2026: Short sales 67.1%
- Nov 11, 2026: Short sales 38.9%
- Nov 12, 2026: Short sales 55%
- Nov 13, 2026: Short sales 30%
- Nov 16, 2026: Short sales 59%
- Nov 17, 2026: Short sales 64.2%
- Nov 18, 2026: Short sales 50.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Deep Track Capital, LPTenPercentOwnerDirectly2.69M
- Ran NussbaumDirectorDirectly–
- Pontifax Management 4 G.P. (2015) Ltd.TenPercentOwnerDirectly–
- Vida Ventures GP III, L.L.C.TenPercentOwnerDirectly–
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Deep Track Capital, LPTenPercentOwner | 2.69M | 666.7K | Sep 12, 2025 | Form 4 |
| Ran NussbaumDirector | – | 1.41M | Sep 12, 2025 | Form 4 |
| Pontifax Management 4 G.P. (2015) Ltd.TenPercentOwner | – | 1.41M | Sep 12, 2025 | Form 4 |
| Vida Ventures GP III, L.L.C.TenPercentOwner | – | 2,029 | Sep 12, 2025 | Form 4 |
A lower bound: it counts only the 4 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IHEiShares U.S. Pharmaceuticals ETFWeight in the fund0.18%
- IWCiShares Micro-Cap ETFWeight in the fund0.16%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.03%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.02%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- SCHBSchwab U.S. Broad Market ETFWeight in the fund0.00%
- ITOTiShares Core S&P Total U.S. Stock Market ETFWeight in the fund0.00%
13 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 53
- Q4 2025: Managers 68
- Q1 2026: Managers 78
- Q2 2026: Managers 115
Q2 2026: 115 managers held 30.81M shares, worth $1.0B. During the quarter 41 opened a position, 6 closed one, 40 added and 13 trimmed.
The largest holders, Q2 2026
- Deep Track CapitalIn the quarter
- BlackRockIn the quarter+11%
- Ra Capital ManagementIn the quarter
- Nantahala Capital ManagementIn the quarter+100%
- Trails Edge Capital PartnersIn the quarter+15%
- Commodore CapitalIn the quarter
- JPMorgan ChaseIn the quarter+4.9%
- TCG Crossover ManagementIn the quarter-21%
- Caligan PartnersIn the quarter
- Spruce Street CapitalIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Deep Track Capital | 3.35M | $109M | |
| BlackRock | 2.73M | +11% | $89M |
| Ra Capital Management | 2.21M | $72M | |
| Nantahala Capital Management | 2.11M | +100% | $68M |
| Trails Edge Capital Partners | 1.52M | +15% | $49M |
| Commodore Capital | 1.50M | $49M | |
| JPMorgan Chase | 1.50M | +4.9% | $49M |
| TCG Crossover Management | 1.45M | -21% | $47M |
| Caligan Partners | 1.44M | $47M | |
| Spruce Street Capital | 1.38M | $45M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do LB Pharmaceuticals's filings show?
Who buys and sells is one part of LB Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have LBRX's insiders bought or sold?
From Jun 5, 2026 to Oct 13, 2026 LB Pharmaceuticals's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold LBRX?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $8.6M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.